COVID-19 ¹é½ÅÀÇ ÇâÈÄ »ç¿ë¿¡ ´ëÇØ 3°³ ´Ù¸¥ ÀáÀçÀû ½Ã³ª¸®¿À°¡ ¿¹ÃøµË´Ï´Ù. 1¹øÂ° ½Ã³ª¸®¿À¿¡¼´Â COVID-19 ¹é½ÅÀÇ ¿¬Â÷ Á¢Á¾ÀÌ ÇÊ¿äÇØÁú °ÍÀ¸·Î »óÁ¤µÇ°í, 2¹øÂ° ½Ã³ª¸®¿À¿¡¼´Â 65¼¼ ÀÌ»ó ÇÏÀ̸®½ºÅ© Áý´ÜÀ¸·ÎÀÇ ¸Å³â ¹é½Å Á¢Á¾, 3¹øÂ° ½Ã³ª¸®¿À¿¡¼´Â 65¼¼ ÀÌ»ó ÇÏÀ̸®½ºÅ© Áý´ÜÀ¸·ÎÀÇ °Ý³â ¹é½Å Á¢Á¾ÀÌ »óÁ¤µÇ°í ÀÖ½À´Ï´Ù.
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19) ¹é½Å ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ÀÌÀü(2021³â 6¿ù ¹ßÇàÇÑ Opportunity Assessment and Forecast to 2026)¿¡¼ ´Ù·é COVID-19 ¹é½ÅÀÇ È¯ÀÚ ±â¹Ý ÆÇ¸Å ¿¹ÃøÀ» Æ÷ÇÔÇÑ Excel ¸ðµ¨À» °»½Å¡¤È®ÀåÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ´ë»ó : ÁÖ¿ä 7°³±¹ ½ÃÀå(¹Ì±¹, ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹, ÀϺ»)
¿¹Ãø±â°£ : 2021-2024³â
Á¶»ç ´ë»ó ¹üÀ§
- ÁÖ¿ä ¿ä¾à
- Áúȯ °³¿ä : ¹ß»ý °æÀ§, º´ÀÎ, º´Å»ý¸®
- ¿ªÇÐ
- ÇöÀç ¹é½Å ¼±ÅûçÇ× : SWOT ºÐ¼®À» Æ÷ÇÔÇÑ »ó¼¼ÇÑ Á¦Ç° ÇÁ·ÎÆÄÀÏ
- ¹ÌÃæÁ· ¼ö¿ä¿Í ±âȸ : Áß¿äÇÑ KOLÀÇ ÀλçÀÌÆ®¿¡ ±â¹ÝÇÑ ÁÖ¿ä ¹ÌÃæÁ· ¼ö¿ä »ó¼¼
- ÆÄÀÌÇÁ¶óÀÎ Æò°¡ : ÆÄÀÌÇÁ¶óÀÎ °³¿ä¿Í SWOT ºÐ¼®À» Æ÷ÇÔÇÑ »ó¼¼ÇÑ Á¦Ç° ÇÁ·ÎÆÄÀÏ
- ¿¬±¸°³¹ß Àü·« : COVID-19 ¹é½Å ÀÓ»ó½ÃÇè ¼³°è¿Í °Å·¡ °áÁ¤ µ¿Çâ
- ½ÃÀå Àü¸Á
KSM 22.02.08
This publication is an update and extension to the Excel model containing the patient-based sales forecast for COVID-19 vaccines, which was previously covered in Coronavirus Disease 2019 (COVID 19) Vaccines: Opportunity Assessment and Forecast to 2026, published in June 2021.
Report deliverables include a PowerPoint report and an interactive Excel-based forecast model
Forecasts includes 7MM (US, France, Germany, Italy, Spain, UK, and Japan)
Forecasts cover 5 years from 2021 to 2026
GlobalData forecast three different potential scenarios for the future use of COVID-19 vaccines -
- The first scenario assumes that annual vaccination with a COVID-19 vaccine will be needed.
- The second scenario assumes annual vaccination for the high-risk population of people 65 years of age and older, while everyone below 65 years of age will need a vaccine only every two years.
- In the third scenario, the high-risk population of people 65 years of age and older will receive a COVID-19 vaccine every two years, while everyone below 65 years will need a vaccine only every five years.
Scope
This report includes -
- Executive Summary
- Disease Overview: History of the outbreak, Etiology and Pathophysiology
- Epidemiology
- Current Vaccination Options: Includes detailed product profiles with SWOT analysis
- Unmet Need and Opportunities: Detailing the major unmet needs with significant KOL insights
- Pipeline Assessment: Includes pipeline overview and detailed product profiles with SWOT analysis
- R&D Strategies: Trends in Clinical Trial Design for COVID-19 Vaccines and Trends in Deal-Making
- Market Outlook
Reasons to Buy
- To understand the current COVID-19 vaccine situation in multiple regions.
- Develop business strategies by understanding the trends shaping and driving the 7MM COVID-19 vaccine.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global COVID-19 vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.